Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.
Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.
BELLINGS Intelligence Score: 8
Why it matters
This is a routine competitive analysis article about Eli Lilly's market position relative to Amylyx, with no direct impact on credit markets or financing conditions.
Sources
Nasdaq
Should Eli Lilly Investors Be Worried About a Threat From Amylyx?
Key PointsEli Lilly generated nearly two-thirds of its sales from GLP-1 drugs in the second quarter of 2026.